PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
ESC Congress Rome 2016
Looking back at 2016
What made the news in 2016? What have we learnt about PCSK9 inhibition?

PCSK9 Forum Editor Professor John Chapman reviews the ups and downs of 2016.

First, the highlights: and four key studies feature:
John Chapman
  • GLAGOV: The first evidence that treatment with a PCSK9 inhibitor on a
    background of optimized, statin therapy regresses coronary atherosclerosis
  • PCSK9 inhibition: Does it increase diabetes risk? Two Mendelian randomization studies provide important insights
  • ESC/EAS Task Force: Much needed practical guidance for the use of PCSK9 inhibitors in patients at very high cardiovascular risk
  • ORION-1: The first in class PCSK9 RNA interference agent, inclisiran
However, the termination of the PCSK9 inhibitor bococizumab was a key disappointment. Professor Chapman discusses why this agent was terminated and the implications for the PCSK9 field.

Read the report and view the videos here »

John Chapman

2017 promises to be a very exciting year with FOURIER, the first of the PCSK9 inhibitor outcomes studies, due to report.

Check back here to follow the latest developments on PCSK9 Forum.

New and updated edition of our popular therapeutic guide

A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition.

Read online » Download now »

Forward to colleagues »
  New eBook
Click here to forward this email to a colleague
Questions & Answers
Why are new treatments needed?
Read the full answer and other questions on the PCSK9 Forum »
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2017. Please click here to unsubscribe from future mailings.